Mirum Pharmaceuticals, Inc. MIRM Research and development expense
Research and development expense at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s research and development expense?
- Mirum Pharmaceuticals, Inc. (MIRM) reported research and development expense of $97.91M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s research and development expense changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s research and development expense increased by 138.5% year-over-year, from $41.04M to $97.91M.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s research and development expense?
- Over 4 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s research and development expense has grown at a 8.4% compound annual growth rate (CAGR), from $131.43M to $181.18M.